Alyeska Investment Group’s Soleno Therapeutics SLNO Stock Holding History

Alyeska Investment Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-217,500	Closed	-$7.28M	–	784
2026 Q1	$7.28M	Hold	217,500	–	–	0.02%	433
2025 Q4	$10.1M	Buy	217,500 +25,000	+13%	+$1.37M	0.03%	389
2025 Q3	$13M	Sell	192,500 -252,852	-57%	-$18.7M	0.04%	341
2025 Q2	$37.3M	Sell	445,352 -83,857	-16%	-$6.28M	0.13%	194
2025 Q1	$37.8M	Buy	529,209 +105,128	+25%	+$5.12M	0.15%	172
2024 Q4	$19.1M	Sell	424,081 -552,024	-57%	-$28.6M	0.07%	264
2024 Q3	$49.3M	Buy	+976,105	New	+$46.7M	0.25%	140

Alyeska Investment Group's SLNO Position: Q2 2026 in Review

Alyeska Investment Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 217,500 shares — an estimated $7.28M sold.

Alyeska Investment Group first reported a position in SLNO in Q3 2024 and held it in 7 quarters. The position peaked at $49.3M in Q3 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Alyeska Investment Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Alyeska Investment Group sold 217,500 Soleno Therapeutics shares in Q2 2026, an estimated $7.28M.
Alyeska Investment Group first reported a position in Soleno Therapeutics in Q3 2024 and held it in 7 quarters.
Alyeska Investment Group's Soleno Therapeutics position peaked at $49.3M in Q3 2024.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.